Health Care·Biotechnology·$2.3B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.74 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.74 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed a cautious approach, highlighting the importance of their current projects. There was no guidance update, leaving investors uncertain about future expectations.
Management did not provide specific guidance for future performance.
The company is focused on its ongoing research and development efforts.
The earnings report indicates that Mineralys Therapeutics is still in a challenging phase, with a significant loss per share. The stock's decline of 3.43% reflects investor concerns over the lack of revenue information and future guidance. Without clear direction from management, investors may remain cautious in their outlook for the company.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SENTINELONE INC Class A
Mar 14, 2023